ReviewBiomedicines2022
Renal Cell Carcinoma in End-Stage Renal Disease: A Review and Update.
Review in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Effects and Clinical Value of Peritoneal Dialysis on Water and Water Balance, Adverse Reactions, Quality of Life, and Clinical Prognosis in Patients with Decompensated Chronic Nephropathy: A Systematic Review and Meta-Analysis.Computational and mathematical methods in medicine · 2022Pooled it
- LDHA-driven ACAA2 lactylation at K270 reprograms fatty acid metabolism to promote clear cell renal cell carcinoma progression.Scientific reports · 2026Article
- Fu Zheng Xiao Yu San Jie Decoction affects the proliferation of renal cell carcinoma via regulatingTranslational andrology and urology · 2025Article
- Association Between Renal Cell Cancer and Chronic Kidney Disease: An Update on a Never-Healing Wound.Biomedicines · 2025Review
- Varieties of altered TFE3 can occur in MiT-family-related renal cell carcinomas.International urology and nephrology · 2025Article
- Machine learning models for predicting interaction affinity energy between human serum proteins and hemodialysis membrane materials.Scientific reports · 2025Article
- From acute tubular injury to tubular repair and chronic kidney diseases - KIM-1 as a promising biomarker for predicting renal tubular pathology.Current research in physiology · 2025Review
- Clinical features and mutational frequency of renal cell carcinoma from patients undergoing kidney transplant evaluation.Frontiers in oncology · 2025Article
- Gastric metastasis subsequent to renal cell carcinoma surgery: a case report.Frontiers in oncology · 2025Article
- TCIRG1 as a Novel Prognostic Biomarker Triggering Immune Infiltration in Renal Clear Cell Carcinoma: An Integrative Study of Single-Cell and Bulk Data.Human mutation · 2025Article
- Report on post-transplantation cancer in southeast Asia from the Thai kidney transplantation cohort.Scientific reports · 2024Article
- Article
- A Rare Case of Donor-Derived Renal Cell Carcinoma in a Kidney Transplant Recipient.The American journal of case reports · 2024Article
- Investigation of APE1 and OGG1 expression in chronic hemodialysis patients.Molecular biology reports · 2024Article
- Identification of prognostic RNA editing profiles for clear cell renal carcinoma.Frontiers in medicine · 2024Article
- Review
- A case of ipsilateral three simultaneous renal cell carcinomas with different histologic types.IJU case reports · 2023Article
- Collision tumor of spindle cell lipoma arising from perirenal tissue and acquired cystic disease-associated renal cell carcinoma: A rare case report.IJU case reports · 2023Article
- Renal Cell Carcinoma in End-Stage Renal Disease: A Retrospective Study in Patients from Hungary.Pathobiology : journal of immunopathology, molecular and cellular biology · 2023Article
- Hyaline Vascular Type of Unicentric Castleman Disease in a Kidney with End-Stage Renal Disease: A Case Report of a Rare Entity at an Unusual Location and a Special Clinical Setting.Diagnostics (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal cell carcinoma (RCC) occurring in the setting of end-stage renal disease (ESRD) shows unique clinicopathological characteristics. The two most frequent types of ESRD-associated RCC are acquired cystic kidney disease-associated renal cell carcinoma (ACKD-RCC) and clear-cell papillary renal cell carcinoma (ccpRCC). Other types of RCC also occur in ESRD, albeit with different frequencies from the non-ESRD general population. The histological features of RCC do not vary in the setting of ESRD vs. non-ESRD, yet other findings, such as multifocality and multiple tumor types, are more frequent in ESRD. Studies have generated novel and important knowledge of the etiology, epidemiology, diagnosis, treatment, immunophenotype, and molecular characteristics of ESRD-associated RCC. Knowledge of these data is important for both pathologists and other physicians who may encounter ESRD patients with RCC. This review presents a comprehensive summary and update of the literature on RCC in ESRD, with a focus on the two most frequent types, ACKD-RCC and ccpRCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.